Johnson & Johnson likely to report mixed results for Q1 FY26
Johnson & Johnson (NYSE: JNJ) ended fiscal 2025 on a high note, reporting higher revenues and strong earnings growth for...
Featured
$ABT
Abbott Laboratories set to report Q1 FY26 earnings. Here’s what to expect
Abbott Laboratories (NYSE: ABT) enters fiscal 2026 with a growing profile, increasingly driven by sustained momentum in medical devices—particularly diabetes…
